DOCSLIB.ORG

FROM QSAR to QNAR, DEVELOPING ENHANCED MODELS for DRUG DISCOVERY By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FROM QSAR to QNAR, DEVELOPING ENHANCED MODELS for DRUG DISCOVERY By FROM QSAR TO QNAR, DEVELOPING ENHANCED MODELS FOR DRUG DISCOVERY by WENYI WANG A dissertation submitted to the Graduate School-Camden Rutgers, the State University of New Jersey In partial fulfillment of the requirements For the degree of Doctor of Philosophy Graduate Program in Computational and Integrative Biology Written under the direction of Dr. Hao Zhu And approved by Dr. Hao Zhu Dr. Sunil Shende ________________________________ ________________________________ Dr. Bing Yan Dr. Suneeta Ramaswami ________________________________ ________________________________ Dr. Jinglin Fu Dr. Joseph Martin ________________________________ ________________________________ Camden, New Jersey October 2018 ABSTRACT OF THE DISSERTATION From QSAR to QNAR, Developing Enhanced Models for Drug Discovery by WENYI WANG Dissertation Director: Dr. Hao Zhu Exploring new chemical entities in drug discovery requires extensive investigations on libraries of thousands of molecules. While conventional animal-based tests in drug discovery procedure are expensive and time consuming, the evaluation of a drug candidate can be facilitated by alternative computational methods. For example, the Quantitative Structure Activity Relationship (QSAR) model has been widely used to predict bioactivities for drug candidates. However, traditional QSAR models are solely based on chemical structures, and are less effective in the drug discovery procedure due to various limitations related to complicated structures or bioactivities. In this thesis, we aimed to establish high quality and predictive models by using novel modeling approaches beyond QSAR. First, we developed a methodology for predicting the Blood- Brain Barrier permeability of small molecules by incorporating biological assay information (e.g. transporter interactions) into the modeling process. This method can be further extended to modeling and predicting in vivo bioactivities of drug candidates. Second, we created a new Quantitative Nanostructure Activity Relationship (QNAR) modeling strategy to extend the applicability of QSAR to predict bioactivities of ii nanomaterials. The research presented in this thesis opens a new path to the precise prediction of bioactivities of molecules in the drug discovery procedure. iii Acknowledgements To my advisor, Dr. Hao Zhu, thank you so much. It was the best choice I ever made to work with you. Your guidance, support and encouragement have been my greatest motivation. Your intelligence, enthusiasm, and ambition have been a great source of inspiration throughout my graduate study. I couldn’t have been who I am now without you. No word can express my gratefulness to you. Thank you! To my committee members, Dr. Bing Yan, Dr. Jinglin Fu, Dr. Sunil Shende, Dr. Suneeta Ramaswami, Dr. Joseph Martin, thank you for your generous support and guidance. To my peer, mentor and friend, Marlene Kim, thank you for your guidance and help. You are my first English-speaking friend. Thank you for walking me through every single detail of research, while tolerating my Chinglish. Our friendship will be my treasure of life. To my lab members and friends, Abena Boison, Marlene Kim, Chris Mayer- Bacon, Dan Pinolini, Kathryn Ribay, Dan Russo, Alexander Sedykh, Yutang Wang, Min Wu, Xiliang Yan, Jun Zhang, Linlin Zhao, thank all of you for making my graduate study enjoyable. I learned from each of you and we accomplished great projects that would not have been realized had we did it ourselves. I will miss spending time with you all. To all my friends at Rutgers-Camden, friends at Society of Toxicology, friends at National Center for Toxicological Research U.S. FDA, friends at Genentech, friends at iv Sanofi, thank all of you for making my graduate life colorful and memorable. Every one of you is very important to me. Call me if you see this! Last but not least, to my dearest family, thank you for everything. To Chengyue, thank you for getting me into graduate school, for the many scientific discussions, your support and compromise. To my dad, thank you for immersing me with science ever since I was born, from genetic to epigenetic. To my mom, thank you for your continuous thoughtfulness, support and care whenever I am down. Love is LOVE. v Dedication To my husband, Chengyue Zhang, and My parents, Min Wang and Guoting Chen vi ABSTRACT OF THE DISSERTATION ........................................................................... ii Acknowledgements ............................................................................................................ iv Dedication .......................................................................................................................... vi TABLE OF CONTENTS .................................................................................................... x List of Figures ..................................................................................................................... x List of Tables .................................................................................................................... xii Chapter 1 Introduction ........................................................................................................ 1 1.1 Computer aided drug design ................................................................................. 1 1.2 QSAR principles and workflow ............................................................................ 2 1.2.1 Data curation .............................................................................................. 2 1.2.2 Chemical descriptors .................................................................................. 3 1.2.3 Machine learning models ........................................................................... 6 1.2.4 Statistical Evaluation of Model Performance ............................................ 7 1.2.5 Validation of models .................................................................................. 8 1.3 Limitation of conventional QSAR and solutions .................................................. 9 Chapter 2 Developing Enhanced Blood-Brain Barrier Permeability Models: Integrating External Bio-assay Data in QSAR Modeling ................................................................... 11 Chapter Overview ..................................................................................................... 11 vii 2.1 Introduction ......................................................................................................... 12 2.2 Methods............................................................................................................... 17 2.2.1 Dataset...................................................................................................... 17 2.2.2 Overview of the Workflow in this Study ................................................. 18 2.2.3 Chemical Descriptors ............................................................................... 19 2.2.4 Modeling and Approaches ....................................................................... 20 2.2.5 Integration of Biological Descriptors ....................................................... 21 2.3 Results ................................................................................................................. 23 2.3.1 Overview of the BBB Permeability Database ......................................... 23 2.3.2 Consensus QSAR Results ........................................................................ 25 2.3.3 Bio-assay Data Improve Model Predictive Power ................................... 26 2.4 Discussion ........................................................................................................... 31 2.5 Conclusion .......................................................................................................... 42 Chapter 3 Predicting Nano-bio Interactions by Integrating Nanoparticle Libraries and Quantitative Nanostructure Activity Relationship Modeling ........................................... 43 Chapter Overview ..................................................................................................... 43 3.1 Introduction ......................................................................................................... 44 3.2 Methods/experimental......................................................................................... 46 3.2.1 GNP library synthesis .............................................................................. 46 3.2.2 GNP library characterization ................................................................... 46 viii 3.2.3 Experimental logP measurement ............................................................. 47 3.2.4 Quantification of HO-1 level ................................................................... 47 3.2.5 Cellular uptake ......................................................................................... 48 3.2.6 Virtual GNP construction and structure optimization ............................. 48 3.2.7 Virtual GNP chemical descriptor calculation .......................................... 49 3.2.8 QNAR modeling ...................................................................................... 50 3.3 Results and discussion ........................................................................................ 51 3.3.1 Workflow of experimental testing, QNAR modeling and rational nanomaterial design. ......................................................................................... 51 3.3.2 Design and synthesis
Load more

Recommended publications
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Report on an NIH Workshop on Ultralarge Chemistry Databases Wendy A
    1 Report on an NIH Workshop on Ultralarge Chemistry Databases Wendy A. Warr Wendy Warr & Associates, 6 Berwick Court, Holmes Chapel, Cheshire, CW4 7HZ, United Kingdom. Email: [email protected] Introduction The virtual workshop took place on December 1-3, 2020. It was aimed at researchers, groups, and companies that generate, manage, sell, search, and screen databases of more than one billion small molecules (Figure 1). There were about 550 “attendees” from 37 different countries. Recent advances in computational chemistry have enabled researchers to navigate virtual chemical spaces containing billions of chemical structures, carrying out similarity searches, studying structure-activity relationships (SAR), experimenting with scaffold-hopping, and using other drug discovery methodologies.1 For clarity, one could differentiate “spaces” from “libraries”, and “libraries” from “databases”. Spaces are combinatorially constructed collections of compounds; they are usually very big indeed and it is not possible to enumerate all the precise chemical structures that are covered. Libraries are enumerated collections of full structures: usually fewer than 1010 molecules. Databases are a way to storing libraries, for example, in a relational database management system. Figure 1. Ultralarge chemical databases. (Source: Marcus Gastreich based on the publication by Hoffmann and Gastreich.) This report summarizes talks from about 30 practitioners in the field of ultralarge collections of molecules. The aim is to represent as accurately as possible the information that was delivered by the speakers; the report does not seek to be evaluative. 2 Welcoming remarks; defining a drug discovery gateway Susan Gregurick, Office of Data Science and Strategy, NIH, USA Data should be “findable, accessible, interoperable and reusable” (FAIR)2 and with this in mind, NIH has been creating, curating, integrating, and querying ultralarge chemistry databases.
    [Show full text]
  • Qsar Methods Development, Virtual and Experimental Screening for Cannabinoid Ligand Discovery
    QSAR METHODS DEVELOPMENT, VIRTUAL AND EXPERIMENTAL SCREENING FOR CANNABINOID LIGAND DISCOVERY by Kyaw Zeyar Myint BS, Biology, BS, Computer Science, Hampden-Sydney College, 2007 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2012 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Kyaw Zeyar Myint It was defended on August 20th, 2012 and approved by Dr. Ivet Bahar, Professor, Department of Computational and Systems Biology Dr. Billy W. Day, Professor, Department of Pharmaceutical Sciences Dr. Christopher Langmead, Associate Professor, Department of Computer Science, CMU Dissertation Advisor: Dr. Xiang-Qun Xie, Professor, Department of Pharmaceutical Sciences ii Copyright © by Kyaw Zeyar Myint 2012 iii QSAR METHODS DEVELOPMENT, VIRTUAL AND EXPERIMENTAL SCREENING FOR CANNABINOID LIGAND DISCOVERY Kyaw Zeyar Myint, PhD University of Pittsburgh, 2012 G protein coupled receptors (GPCRs) are the largest receptor family in mammalian genomes and are known to regulate wide variety of signals such as ions, hormones and neurotransmitters. It has been estimated that GPCRs represent more than 30% of current drug targets and have attracted many pharmaceutical industries as well as academic groups for potential drug discovery. Cannabinoid (CB) receptors, members of GPCR superfamily, are also involved in the activation of multiple intracellular signal transductions and their endogenous ligands or cannabinoids have attracted pharmacological research because of their potential therapeutic effects. In particular, the cannabinoid subtype-2 (CB2) receptor is known to be involved in immune system signal transductions and its ligands have the potential to be developed as drugs to treat many immune system disorders without potential psychotic side- effects.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Open Chemoinformatic Resources to Explore the Structure, Properties and Chemical Space of Cite This: RSC Adv.,2017,7,54153 Molecules
    RSC Advances REVIEW View Article Online View Journal | View Issue Open chemoinformatic resources to explore the structure, properties and chemical space of Cite this: RSC Adv.,2017,7,54153 molecules a ab a Mariana Gonzalez-Medina,´ J. Jesus´ Naveja, Norberto Sanchez-Cruz´ a and Jose´ L. Medina-Franco * New technologies are shaping the way drug discovery data is analyzed and shared. Open data initiatives and web servers are assisting the analysis of the large amounts of data that we are now able to produce. The final goal is to accelerate the process of moving from new data to useful information that could lead to Received 27th October 2017 treatments for human diseases. This review discusses open chemoinformatic resources to analyze the Accepted 21st November 2017 diversity and coverage of the chemical space of screening libraries and to explore structure–activity DOI: 10.1039/c7ra11831g relationships of screening data sets. Free resources to implement workflows and representative web- rsc.li/rsc-advances based applications are emphasized. Future directions in this field are also discussed. Creative Commons Attribution 3.0 Unported Licence. 1. Introduction connections between biological activities, ligands and proteins.3 During the past few years, there has been an important increase Herein we review representative chemoinformatic tools in open data initiatives to promote the availability of free essential to explore the structure, chemical space and properties research-based tools and information.1 While there is still some of molecules. The review is focused on recent and representative resistance to open data in some chemistry and drug discovery free web-based applications.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Chromatographic Analysis of Pharmaceuticals Second Edition, Revised and Expanded
    Chromatographic Analysis of Pharmaceuticals Second Edition, Revised and Expanded edited by John A. Adamovics Cytogen Corporation Princeton, New Jersey Marcel Dekker, Inc. New York-Basel «Hong Kong Preface ISBN: 0-8247-9776-0 The first edition of Chromatographic Analysis of Pharmaceuticals was The publisher offers discounts on this book when ordered in bulk quanti­ published in 1990. The past years have allowed me to evaluate leads that I ties. For more information, write to Special Sales/Professional Marketing uncovered during the researching of the first edition, such as the first pub­ at the address below. lished example of the application of chromatography to pharmaceutical analysis of medicinal plants. This and other examples are found in a rela­ This book is printed on acid-free paper. tively rare book, Uber Kapillaranalyse und ihre Anwendung in Pharmazeu- tichen Laboratorium (Leipzig, 1992), by H. Platz. Capillary analysis, the Copyright © 1997 by Marcel Dekker, Inc. All Rights Reserved. chromatographic technique used, was developed by Friedlieb Runge in the mid-1850s and was later refined by Friedrich Goppelsroeder. The principle Neither this book nor any part may be reproduced or transmitted in any of the analysis was that substances were absorbed on filter paper directly form or by any means, electronic or mechanical, including photocopying, from the solutions in which they were dissolved; they then migrated to microfilming, and recording, or by any information storage and retrieval different points on the filter paper. Capillary analysis differed from paper system, without permission in writing from the publisher. chromatography in that no developing solvent was used. We find that, from these humble beginnings 150 years ago, the direct descendant of this Marcel Dekker, Inc.
    [Show full text]
  • Pharmaceuticals
    Tel. +27‐51‐401‐3344 www.liquidtech.co.za FAX +27‐51‐401‐9069 Analysis: Qualitative Package: Pharmaceuticals Aceclidine Bupivacaine Dihydroergotamine Aceprometazine Bupranolol Dilazep Aciclovir Buprenorphine Diltiazem Ajmaline Buspirone Diphenhydramine Aldicarb Sulphone Butaperazine Dipyridamole Aldicarb‐sulfoxide Caffeine Disopyramide alpha‐Hydroxyalprazolam Carazolol Dixyrazine alpha‐Hydroxytriazolam Carbamazepine Doxapram Alprazolam Carbinoxamine Doxepin Alprenolol Carbuterol Ecgoninemethylester Amantadine Carteolol Embutramide Amiloride Carvedilol Enalapril Aminoclonazepam 7‐ Celiprolol Ephedrine Aminoflunitrazepam 7‐ Cetirizine Eprosartan Aminonitrazepam 7‐ Chlorcyclizine Esmolol Aminophenazone Chlordiazepoxide Estazolam Aminopromazine Chlorphenethiazine Ethenzamide Amiodarone Chlorpheniramine Felodipine Amiphenazole Chlorpromazine Fenarimol Amitriptylin Chlorprothixene Fendiline Amoxicillin Cilazapril Fenetylline Amphetamine Cinnarizine Fenfluramine Apomorphine Citalopram Fentanyl Aprinidine Clemastine Fexofenadine Atenolol Clenbuterol Flecainide Atorvastatin Clobazam Fluconazole Atropine Clobutinol Flufenoxuron Aztreonam Clomethiazole Flunitrazepam Befunolol Clomipramine Fluoxetine Bendiacarb Clonazepam Fluphenazine Benzatropine Clonidine Flurazepam Benzocaine Clozapine Fluvoxamine Benzoctamine Cocaine Gabapentin Benzoylecgonine Codeine Gallopamil Berberine Coumatetralyl Glibenclamide Betaxolol Cyclicine Glibornuride Bezafibrate Demeton‐S‐methyl Glimepiride Biperiden Desalkylflurazepam Glipizide Bisoprolol Desipramine Gliquidone
    [Show full text]
  • Selective Reaction Monitoring (SRM) Daten Von Mehr Als 900 Xenobiotika Für Aufbau Und Validierung Von LC-MS/MS Analysen
    T + K (2008) 75 (3): 149 Selective Reaction Monitoring (SRM) Daten von mehr als 900 Xenobiotika für Aufbau und Validierung von LC-MS/MS Analysen Brunhilde Güssregen, Stefanie Schröfel, Markus Nauck, Torsten Arndt Bioscientia Institut für Medizinische Diagnostik GmbH, Konrad-Adenauer-Str. 17, 55218 Ingelheim; e-mail: [email protected] Die Flüssigkeitschromatographie-Tandem-Massenspektrometrie (LC-MS/MS) hat in den letz- ten Jahren eine zunehmende Bedeutung nicht nur in der klinisch-chemischen sondern auch in der toxikologischen Analytik gewonnen. Sie kann heute neben den klassischen Verfahren wie UV/VIS-Spektrometrie, Hochleistungs-Flüssigkeitschromatographie (HPLC) und Gaschro- matographie-Massenspektrometrie (GC-MS) als integraler Bestandteil der qualitativen und quantitativen Analytik gewertet werden. Dies drückt sich nicht zuletzt in der steigenden Zahl der Meldungen von mit LC-MS/MS erhobenen GTFCh- Ringversuchsergebnissen aus. Die Ursachen für diese Popularität sind vielfältig. Es sind u. a. einige analytische Vorteile im Vergleich zu den o. g. Analysentechniken: Vereinfachte Probenvorbereitung (z. B. ohne Derivatisierungsreaktionen), Einsatz geringerer Probenmengen, Kürzere Chromatographie- und dadurch Analysezeiten, Spezifitätssteigerung durch die Kombination von minimal 4 Identifizierungskriterien (Retentionszeit, Massenübergänge 1 und 2 [SRM 1 und SRM 2], Intensitätsverhältnis von SRM1 und SRM2), deren Anzahl bei Verwendung von mehr als 2 SRM erhöht werden kann, Eignung für alle löslichen Substanzen unabhängig von ihrer Fähigkeit, zerstörungs- frei in die Gasphase überführt werden zu können. Derzeitige Nachteile der LC-MS/MS im Methodenvergleich sind: Fehlende Standardisierung sowohl der Chromatographie- als auch der Tandem-Mas- senspektrometrie-Analysenteilschritte, Variabilität der Massenspektren infolge der vglw. milden Fragmentierungsbedingun- gen, Fehlen von allgemein verfügbaren LC-MS/MS-Spektren- und/oder Massenübergangs (SRM)-Bibliotheken mit einer der Pfleger-Maurer-Weber Bibliothek [1] oder der Pragst et al.
    [Show full text]
  • Sustained-Release Compositions Containing Cation Exchange Resins and Polycarboxylic Polymers
    ~" ' Nil II II II II Ml Ml INI MINI II J European Patent Office *»%r\ n » © Publication number: 0 429 732 B1 Office_„. europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 16.03.94 © Int. CI.5: A61 K 9/06, A61 K 9/1 8, A61 K 47/32 © Application number: 89312590.6 @ Date of filing: 01.12.89 © Sustained-release compositions containing cation exchange resins and polycarboxylic polymers. @ Date of publication of application: (73) Proprietor: ALCON LABORATORIES, INC. 05.06.91 Bulletin 91/23 6201 South Freeway Fort Worth Texas 76107(US) © Publication of the grant of the patent: 16.03.94 Bulletin 94/11 @ Inventor: Janl, Rajni 4621 Briarhaven Road © Designated Contracting States: Fort Worth, Texas 76109(US) AT BE CH DE FR GB IT LI LU NL SE Inventor: Harris, Robert Gregg 3224 Westcliff Road W. © References cited: Fort Worth, Texas 76109(US) EP-A- 0 254 822 J.Pharm. SCI., vol. 60, no. 9, September 1971, © Representative: Jump, Timothy John Simon et pages 1343-1345 A. HEYD:"Polymer-drug in- al teraction: stability of aqueous gels contain- Venner Shipley & Co. ing neomycin sulfate" 20 Little Britain London EC1A 7DH (GB) 00 CM CO o> CM Note: Within nine months from the publication of the mention of the grant of the European patent, any person ® may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition CL shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee LU has been paid (Art.
    [Show full text]
  • Retro Drug Design: from Target Properties to Molecular Structures
    Retro Drug Design: From Target Properties to Molecular Structures Yuhong Wang*, Sam Michael, Ruili Huang, Jinghua Zhao, Katlin Recabo, Danielle Bougie, Qiang Shu, Paul Shinn, Hongmao Sun* National Center for Advancing Translational Sciences (NCATS) 9800 Medical Center Drive, Rockville, MD 20850 *Contact information for the corresponding authors: Yuhong Wang Hongmao Sun, PhD NCATS/NIH NCATS/NIH 9800 Medical Center Dr. 9800 Medical Center Dr. Rockville, MD 20854 Rockville, MD 20854 Phone: 301-480-9855 Phone: 301-480-9839 e-mail: [email protected] e-mail: [email protected] Abstract: To generate drug molecules of desired properties with computational methods is the holy grail in pharmaceutical research. Here we describe an AI strategy, retro drug design, or RDD, to generate novel small molecule drugs from scratch to meet predefined requirements, including but not limited to biological activity against a drug target, and optimal range of physicochemical and ADMET properties. Traditional predictive models were first trained over experimental data for the target properties, using an atom typing based molecular descriptor system, ATP. Monte Carlo sampling algorithm was then utilized to find the solutions in the ATP space defined by the target properties, and the deep learning model of Seq2Seq was employed to decode molecular structures from the solutions. To test feasibility of the algorithm, we challenged RDD to generate novel drugs that can activate µ opioid receptor (MOR) and penetrate blood brain barrier (BBB). Starting from vectors of random numbers, RDD generated 180,000 chemical structures, of which 78% were chemically valid. About 42,000 (31%) of the valid structures fell into the property space defined by MOR activity and BBB permeability.
    [Show full text]
  • A Chemaxon/KNIME Based Tool for Designing Chemical Libraries
    A ChemAxon/KNIME based tool for designing chemical libraries Tim Parrott Brock Luty Dart NeuroScience Dart NeuroScience September 25, 2013 ChemAxon UGM Dart NeuroScience Small molecules to maintain cognitive vitality (LTM) Currently about 200 FTEs with build-out expected at 260 Privately held LLC by a single individual Scientific Computing Scientific Computing collaborates with other DNS Departments to deliver solutions that simplify and accelerate the drug discovery process. We rely on our (non-traditional) knowledge and experience in both Science and Technology to develop novel and efficient systems to meet this goal Scientific Computing Groups Computational Bioinformatics Chemistry Project Support Project Support - Modeling Philip Cheung - Target ID *Tami Marrone - SBDD/Library Design Doug Fenger - Expression Analysis / Pathways Meg McCarrick + 1 FTE James Na - Apply Methods - Novel Software algorithms Amy Shih - Pre-LO/LO/PCC - Enterprise Software (with Methods) Bill Sinko Information Methods Management Development Software Development Data / Biz Analysis - Informatics Software Development - Data Capture + 1 Group Lead Ron Blanford - Developing new methods John Jaeger - Analytics Daniel Garden - Enterprise Scale Architecture Tim Parrott - Data Access Kevin Neal - RIA (MVC) with SOA James Harr Hari Muddana - QA/Scientific Support - Extensions for ELN, Spotfire, IJC, etc Eileen Tompkins - Project Management + 1 FTE Heather Jones Background Dart NeuroScience (DNS) 200+ Scientists 50+ Chemists Parallel Synthesis Group We need a About 20
    [Show full text]